Xeraya Capital

Xeraya Capital is a prominent private equity and venture capital firm based in Kuala Lumpur, Malaysia, with a dedicated focus on the global life sciences sector. Established in 2012, the firm operates as a unit of Khazanah Nasional Berhad, Malaysia's sovereign wealth fund, providing it with substantial financial backing and a long-term investment horizon. Xeraya Capital's mandate is to identify and invest in breakthrough technologies and innovative solutions that address significant unmet medical needs across various therapeutic areas and medical technologies worldwide.

The firm's investment strategy is comprehensive, spanning across different stages of company development, from early-stage ventures requiring initial capital to more mature companies seeking growth equity. Xeraya Capital seeks to build long-term partnerships with its portfolio companies, actively contributing to value creation beyond just capital injection. Their global outlook means they are not restricted by geography, actively seeking opportunities in key life science hubs around the world.

Xeraya Capital typically deploys significant capital in its investments. Their first cheque sizes generally range from US$10 million to US$40 million per deal, reflecting their commitment to substantial stakes in promising life science companies. This strategic approach allows them to support companies through critical development phases, from clinical trials to market commercialization. Their portfolio reflects a diverse range of companies involved in biotechnology, pharmaceuticals, and medical devices, underscoring their broad interest within the life sciences ecosystem.